TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
32.03
+0.08 (0.25%)
Nov 24, 2025, 4:00 PM EST - Market closed
TG Therapeutics Employees
TG Therapeutics had 338 employees as of December 31, 2024. The number of employees increased by 74 or 28.03% compared to the previous year.
Employees
338
Change (1Y)
74
Growth (1Y)
28.03%
Revenue / Employee
$1,573,663
Profits / Employee
$1,323,885
Market Cap
4.68B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 338 | 74 | 28.03% |
| Dec 31, 2023 | 264 | 38 | 16.81% |
| Dec 31, 2022 | 226 | -60 | -20.98% |
| Dec 31, 2021 | 286 | 14 | 5.15% |
| Dec 31, 2020 | 272 | 138 | 102.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TGTX News
- 6 days ago - TG Therapeutics: Concerns About Slowing Growth And New Competition - Seeking Alpha
- 7 days ago - TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing - Seeking Alpha
- 21 days ago - TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows - Seeking Alpha
- 21 days ago - TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 27 days ago - TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI - GlobeNewsWire
- 2 months ago - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment - GlobeNewsWire
- 2 months ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting - GlobeNewsWire